K-V Pharmaceutical Company Secures $20 Million Loan

September 14, 2010, St. Louis, MO. - K-V Pharmaceutical Company (NYSE: KVa/KVb) announced today that it has entered into an agreement with U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C. for a $20 million loan secured by assets of the Company. K-V will utilize the proceeds of the loan for working capital and general operating purposes.

The Company, upon the request of U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C., has entered into a period of exclusivity to negotiate an expanded, longer-term financial arrangement that will align with the Company's future strategic plans.

Under the terms of the loan agreement, which expires January 31, 2011, the Company will pay interest at an annual rate of 16.5%, of which 5% is Payment-in-Kind (PIK). The exclusivity period expires September 28, 2010.

Greg Divis, Interim President and Chief Executive Officer of K-V stated, "The entire Company, along with the Board of Directors have worked hard to secure this agreement which comes shortly after our receiving approval from the U.S. Food and Drug Administration ("FDA") to return our first product to the market. This financing is another important step in returning the Company to normalized operations."

The Company intends to raise additional capital beyond this $20 million loan to provide for ongoing operations beyond the fourth quarter of calendar 2010.

About KV Pharmaceutical Company

K-V Pharmaceutical Company is a fully-integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology-distinguished branded prescription products. The Company markets its technology-distinguished products through Ther-Rx Corporation, its branded drug subsidiary.

For further information about K-V Pharmaceutical Company, please visit the company's corporate Web site at www.kvpharmaceutical.com.

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.